Skip to main content
. 2018 Sep 20;12:76–84. doi: 10.1016/j.conctc.2018.09.004

Table 3.

Multilevel Regression Outcomes: Phase 1 (Baseline to 3 months) and Phase 2 (3- to 6- months).

N = 67
Intervention n = 33 (Received Fit&Trim @ P1)
Waitlist Control n = 34 (Received Fit&Trim @ P2)
Cross-level Interactions (95% CI) Cohen d
Estimated
Estimated
Outcome measures Mean Simple Slope (95%CI)c Mean Simple Slope (95% CI)c
Weight (%) P1 - BL −0.32 −0.31
P1-3Mod −4.62 −1.4 (-1.9, -.92)a −1.19 - 0.29 (−.63, .05) a −1.1 (-1.7, -0.53)
P2-3Mod −4.40 −1.31
P26Mo −5.55 −0.38 (-.71, -.06)b −6.08 - .75 (-.92, -.58)b −1.6 (-2.10, -1.09)
Weight (kg) P1 - BL 82.78 79.81
P1-3Mod 79.39 −1.1 (-1.56, -.70)a 78.99 -.28 (-.54, -0.01)a −0.85 (-1.4, -0.35) 0.93
P2-3Mod 78.85 78.90
P26Mo 77.87 −0.33 (-.62, -.03)b 75.24 −1.2 (-1.6, -.81)b −0.90 (-1.4, -0.39)
Body Mass Index (kg/m2) BL 30.53 30.46
P1b 29.27 −1.2 (-1.76, -.81) 30.15 - 0.32 (- .66, -.02) −0.93 (-1.5, -0.40)
P2b 28.91 - .37 (-.69, -.07) 28.75 −1.4 (-1.9, - .93) −1.0 (-1.6, -0.47)
Waist Circumference (cm) BL 99.65 98.29
P1b 93.53 −6.1 (-8.4, -4.2) 97.06 −1.2 (−2.5, .01) −4.9 (-7.5, -2.6)
P2 93.30 - .22 (−1.4, 1.1) 92.52 −4.5 (-6.8, -2.3) −4.3 (-6.8, -1.8)
Fasting Plasma Glucose (mg/dl) BL 89.58 92.08
P1b 88.68 -.90 (−4.5, 3.2) 92.54 .45 (−2.5, 3.1) −1.4 (−5.9, 3.6)
P2b 91.39 2.7 (−1.0, 7.7) 91.34 −1.2 (−3.3, .88) 3.9 (−0.3, 9.3)
A1c (%) BL 5.815 5.876
P1b 5.738 - .08 (- .17, .003) 5.900 .02 (- .04, .08) -.10 (−.21, .002)
P2b 5.739 .001 (−.07, .07) 5.811 -.09 (- .16, .02) -.09 (−.19, .008)

Bolded numbers = Statistical significance indicated by NO “0” in 95% CI; BL=Baseline; P1 = Phase 1; P2 = Phase 2 a = Estimated Simple Slope BL to 3Mo; b = Estimated Simple Slope 3Mo to 6Mo; c = Nonparametric bias corrected bootstrapped 95% CI Cross-level interaction = between group difference in simple slopes; d = slightly different means were used for P1- and P2—3Mo Simple Slope weight (kg and %) regression analysis to accommodate all seven monthly data points from baseline to 6 Mo.